Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.51 |
| ▸ | CDK9 | P50750 | 2/20 | 0.51 |
| ▸ | JUND | P17535 | 1/20 | 0.48 |
| ▸ | FOSB | P53539 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL26600675 | 0.92 | HTR1A (0.54) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL24350922 | 0.88 | CHRM4 (0.51) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 | |
| Trifluoroacetic Acid SCHEMBL16755787 | 0.87 | HTR1A (0.50) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| Trifluoroacetic Acid SCHEMBL30619018 | 0.85 | HTR1A (0.48) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL16880332 | 0.82 | CHRM4 (0.47) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 | |
| SCHEMBL31266256 | 0.79 | CHRM4 (0.47) | HTR1ASLC6A2SLC6A4SLC6A3CHRM4 | |
| SCHEMBL6926028 | 0.79 | CHRM4 (0.54) | CHRM4 | |
| SCHEMBL12210552 | 0.79 | HTR1A (0.44) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL3212767 | 0.78 | HTR1A (0.55) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| Hydrochloric Acid SCHEMBL27769607 | 0.77 | HTR2C (0.54) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-03-01 | — | — | US | disclosed |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-10584103-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190023665-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford Burnham Prebys Medical Discovery Institute | 2019-01-24 | — | — | US | disclosed |
| US-10118902-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2018-11-06 | — | — | US | disclosed |
| EP-2953940-B1 | PIPERIDIN-1-YL AND AZEPIN-1-YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20170183338-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-29 | — | — | US | disclosed |
| EP-3160961-A2 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford-Burnham Medical Research Institute (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9593106-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-03-14 | — | — | US | disclosed |
| US-9593106-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-03-14 | — | — | US | disclosed |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| WO-2015200534-A2 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-30 | — | — | WO | disclosed |
| EP-2953940-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014122474-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014122474-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584103-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | HTR1A 116/4885SLC6A2 322/4885SLC6A4 430/4885 |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | HTR1A 116/4885SLC6A2 322/4885SLC6A4 430/4885 |
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | CHRM1, CHRM2, CHRM4 | HTR1A 95/4885SLC6A2 1750/4885SLC6A4 996/4885 |
| US-10118902-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | HTR1A 116/4885SLC6A2 322/4885SLC6A4 430/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | HTR1A 4232/4885SLC6A2 4863/4885SLC6A4 4703/4885 |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | HTR1A 95/4885SLC6A2 1750/4885SLC6A4 996/4885 |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | HTR1A 116/4885SLC6A2 322/4885SLC6A4 430/4885 |
| US-20190023665-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | HTR1A 116/4885SLC6A2 322/4885SLC6A4 430/4885 |
| US-20170183338-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | HTR1A 95/4885SLC6A2 1750/4885SLC6A4 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.